Status:
RECRUITING
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Lead Sponsor:
AstraZeneca
Conditions:
Biliary Tract Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients wit...
Eligibility Criteria
Inclusion
- Key inclusion Criteria:
- Histologically confirmed adenocarcinoma of the biliary tract, including intra-hepatic or extra-hepatic cholangiocarcinoma (CCA) and gallbladder carcinoma (GBC).
- Unresectable locally advanced or metastatic BTC, previously untreated in the advanced disease setting
- Known PD-L1 status assessed at a central laboratory using an acceptable tumor sample.
- Measurable disease by RECIST 1.1 criteria using CT or MRI and is suitable for accurate repeated measurements.
- ECOG Performance Status of 0 or 1 with no deterioration (ie, ECOG PS \> 1) over the previous 2 weeks prior to baseline at screening and prior to randomization.
- Adequate bone marrow and organ function.
- Key exclusion Criteria:
- Ampullary carcinoma
- Any prior systemic therapy received for unresectable, locally advanced or metastatic BTC.
- Any prior exposure to any other therapy targeting immune-regulatory receptors or mechanisms.
- Any concurrent chemotherapy, radiotherapy, immunotherapy, investigational, biologic, or hormonal therapy for cancer treatment other than those under investigation in this study.
- Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment.
- Active or ongoing interstitial lung disease/pneumonitis (of any grade), serious chronic gastrointestinal conditions associated with diarrhea, or active non-infectious skin disease (including any grade rash, urticaria, dermatitis, ulceration, or psoriasis) requiring systemic treatment.
Exclusion
Key Trial Info
Start Date :
December 4 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 4 2029
Estimated Enrollment :
1100 Patients enrolled
Trial Details
Trial ID
NCT07221253
Start Date
December 4 2025
End Date
July 4 2029
Last Update
January 8 2026
Active Locations (162)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Birmingham, Alabama, United States, 35233
2
Research Site
Phoenix, Arizona, United States, 85054
3
Research Site
Tucson, Arizona, United States, 85719
4
Research Site
Duarte, California, United States, 91010